The MDx Impact Grants, an initiative of Nature Awards in partnership with Seegene, are designed to advance the democratization of PCR-based diagnostics for unmet clinical needs. The 2026-2027 cycle directs this mission toward neurodegenerative disease, specifically Alzheimer's disease, challenging researchers to leverage high-multiplex PCR platforms for the detection and characterization of molecular markers. This is not a conventional arts grant; it is a targeted research funding call that demands rigorous scientific inquiry and a clear path to clinical utility. Successful applicants will gain access to Seegene's proprietary syndromic PCR technology and receive development grants of up to 600,000 USD to conduct clinical studies. The program is open to eligible research groups worldwide, with no application fee, and each group may submit only one application focused on the designated project. The scope is deliberately narrow: proposals must articulate how Seegene's platform can address specific gaps in Alzheimer's diagnostics, from early detection to molecular subtyping. The curatorial vision here is one of translational impact. Nature Awards seeks projects that are not merely technically feasible but clinically meaningful, with the potential to improve patient outcomes through accurate, accessible testing. The jury will look for a synthesis of methodological innovation and real-world applicability, prioritizing work that can move from bench to bedside within the grant period.